Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 6Prostatic Neoplasms 5Glioma 2Glioblastoma 2Disease 2Urinary Bladder Neoplasms 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 44Gemcitabine 23Nivolumab 21enfortumab vedotin 20Cisplatin 17avelumab 16Magnetic Resonance Spectroscopy 16Carboplatin 14atezolizumab 13Specimen Handling 12Docetaxel 11sacituzumab govitecan 9Paclitaxel 8Ipilimumab 8durvalumab 6Mitomycin 5Fluorodeoxyglucose F18 5cabozantinib 4Taxes 4toripalimab 3pemigatinib 3erdafitinib 3X-Rays 3Radiosurgery 3Platinum 3Pemetrexed 3Immunoglobulin G 3CTLA-4 Antigen 3Biopsy 3ALT-803 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × fluciclovine F-18 × 1 year × Clear all
NCT04018053 2026-01-27

18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

Brigham and Women's Hospital

Phase EARLY_PHASE1 Active not recruiting
16 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡